BackXTL Biopharmaceuticals Overview

XTL Biopharmaceuticals Profit Margin

XTL Biopharmaceuticals (XTLB.TA) has a profit margin of -651.65%, below the Healthcare sector average of 17.63%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-1063.83%

As of Jun 2025

Annual Profit Margin (TTM)

-651.65%

Trailing 12 months ending Jun 2025

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

XTL Biopharmaceuticals (XTLB.TA) FAQ

The latest profit margin for XTLB.TA is -651.65% as of June 2025. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside XTL Biopharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, XTLB.TA currently prints -651.65% for profit margin, while the sector average sits near 17.63%. That is roughly 3796.6% below the sector mean. Large gaps often invite a closer look at XTL Biopharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively XTL Biopharmaceuticals converts resources into returns. At -651.65%, XTLB.TA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting XTLB.TA's profit margin (-651.65%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack XTL Biopharmaceuticals's profit margin against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.